Drug intelligence / Profile preview

Xilatril

Development stage: Unknown
Lead developer: Laboratorios Dermatológicos Darier
Modality: Small Molecules
Administration: Oral

Overview

Xilatril is a pharmaceutical drug containing terbinafine, an antifungal agent. It is administered orally and works by inhibiting squalene epoxidase, an enzyme essential for ergosterol synthesis in fungal cell membranes. This action leads to a depletion of ergosterol and an accumulation of squalene, both of which are toxic to fungi, ultimately resulting in fungal cell death. Xilatril is manufactured by Laboratorios Dermatológicos Darier and is used to treat various fungal infections, particularly those affecting the skin, hair, and nails.

Brand names: Xilatril

Targets

SQLE (Squalene monooxygenase)

Beyond the preview

Go deeper on Xilatril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xilatril.

Explore the full profile